Zivo Bioscience, Inc.

Market Cap $67.50M
Debt $439.38K
Cash $517.19K
EV $67.42M
FCF -

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$16.32M
EBIT	-$16.29M
ROA	-1K%
Equity	-$1.62M
Growth Stability	1
PE	-4.14
PB	-41.74
P/S	555.57
Price/Cash	0.01
Debt/Equity	-0.27
Gross Margins	30%
Op. Margins	-13K%
Sales Growth YoY	-100%
Sales Growth QoQ	-100%
Sales CAGR	2%
Equity CAGR	-0%
Earnings Growth YoY	229%
Earnings Growth QoQ	163%

Sales CAGR 5Y	21%
Equity CAGR 5Y	-1%
Earnings CAGR 3Y	412%
Sales CAGR 3Y	412%
Market Cap	$67.50M
Revenue	$121.50K
Assets	$1.33M
Total Debt	$439.38K
Cash	$517.19K
Shares Outstanding	3.75M
EV	67.42M
Working Capital	-1.59M
Current Ratio	0.39
Gross Profit	$36.45K
Shares Growth 3y	19%
Equity Growth QoQ	214%
Equity Growth YoY	-29%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Zivo Bioscience Inc is a biotechnology company that is engaged in selling natural bioactive ingredients derived from proprietary algae cultures to animal, human and dietary supplement and medical food manufacturers. The company focuses on research and identification of its bioactive ingredients. It also develops tests that allow people to optimize their health and identify future health risks. The company's product candidate ZIVO algae strain is a human dietary supplement that acts as a source of non-animal nutrition, animal supplement, and livestock feed additive, boosting productivity and overall health. Its other product categories are animal applications, human applications, functional food ingredient, dietary supplements and nutraceuticals, and medical food and Botanical Drug.

SEC Filings

Direct access to Zivo Bioscience, Inc. (ZIVO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Zivo Bioscience, Inc. compare to its competitors?

Not enough data to generate a comparison chart between Zivo Bioscience, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Zivo Bioscience, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Zivo Bioscience, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Zivo Bioscience, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-	-	-	-46K%	-	-	-28K%	-9K%	-
ROA	-	-473%	-150%	-1K%	-2K%	-4K%	-101%	-411%	-1K%	-813%	-1K%
ROE	-	44%	62%	66%	138%	81%	-152%	82K%	353%	3K%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-0.61	-0.74	-	-	-	-0.46	0.04	-9.97	-0	-0	-0.27
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-0.27)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-100%	-	-	469%	21%
Earnings YoY growth	-	5%	66%	46%	-21%	-21%	1%	-5%	-11%	72%	-
Equity YoY growth	-	43%	20%	37%	-63%	36%	-153%	-100%	21K%	-77%	-1%
FCF YoY growth	-	-	-	-	-	-	-	-	-	-	-